FRHC
Freedom Holding Corp.
FRHC offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
MS
Morgan Stanley
MS has the edge over FRHC overall, supported by stronger valuation and lower modeled downside.
FRHC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
FRHC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like FRHC.
MS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
MS's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like MS.
FRHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $35.61 | -77% |
| Forward | 25x | $158 | — |
| Fair | 36x | $90.74 | -43% |
| Current | 62x | $158 | — |
| Expensive | 82x | $209 | +32% |
Historical ranges are pointers, not guarantees.
FRHC's PE is in its expensive range at 62x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
MS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $134 | -29% |
| Fair | 14x | $178 | -5.7% |
| Forward | 14x | $189 | — |
| Current | 15x | $189 | — |
| Expensive | 18x | $223 | +18% |
Historical ranges are pointers, not guarantees.
MS has the edge over FRHC in the historical PE scenario, which offers more potential upside but is not a forecast.
FRHC Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for FRHC, with profitability improving.
MS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MS, with profitability improving.
FRHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.30 | +149% |
| Q2 2026 | $2.53 | +90% |
| Q1 2026 | $2.51 | +79% |
| Q4 2023 | $5.35 | +302% |
| Q3 2023 | $5.08 | +512% |
| Q2 2023 | $3.57 | -6.8% |
| Q1 2023 | $3.45 | -6% |
| Q4 2022 | $1.33 | -78% |
| Q3 2022 | $0.83 | -86% |
FRHC's earnings per share have fallen from their peak: $2.53 over the past year, against $6.08 in late 2021.
MS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.39 | +6.3% |
| Q3 2026 | $12.60 | +29% |
| Q2 2026 | $12.37 | +40% |
| Q1 2026 | $11.04 | +29% |
| Q4 2025 | $10.21 | +28% |
| Q3 2025 | $9.76 | +48% |
| Q2 2025 | $8.84 | +45% |
| Q1 2025 | $8.53 | +55% |
| Q4 2024 | $7.95 | +53% |
MS has the edge over FRHC on earnings, with more consistent year-over-year improvement.
FRHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $732.5M | +37% |
| Q1 2026 | $503.1M | +38% |
| Q4 2025 | $628.6M | -4.1% |
| Q3 2025 | $526.1M | -9.4% |
| Q2 2025 | $533.4M | +18% |
| Q1 2025 | $363.7M | -22% |
| Q4 2024 | $655.2M | +57% |
| Q3 2024 | $580.9M | +33% |
FRHC's revenue is growing: $733M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 5.6% | -2 points |
| Q1 2026 | 6.2% | +49 points |
| Q4 2025 | 15% | -0.1 points |
| Q3 2025 | 12% | -11 points |
| Q2 2025 | 7.6% | -1.6 points |
| Q1 2025 | -43% | -65 points |
| Q4 2024 | 15% | -12 points |
| Q3 2024 | 22% | -8.8 points |
FRHC's operating margin was 5.6% last quarter, down 2 points from the same quarter a year ago, near the bottom of its range since 2019.
MS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.3B | +12% |
| Q2 2026 | $21.3B | +27% |
| Q1 2026 | $20.6B | +16% |
| Q4 2025 | $17.9B | +10% |
| Q3 2025 | $18.2B | +18% |
| Q2 2025 | $16.8B | +12% |
| Q1 2025 | $17.7B | +17% |
| Q4 2024 | $16.2B | +26% |
MS's revenue has grown year over year for 14 quarters in a row: $20.3B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | -1.2 points |
| Q2 2026 | 34% | +6.9 points |
| Q1 2026 | 34% | +2.8 points |
| Q4 2025 | 32% | +2 points |
| Q3 2025 | 33% | +5.6 points |
| Q2 2025 | 28% | +0.4 points |
| Q1 2025 | 31% | +2.2 points |
| Q4 2024 | 30% | +14 points |
MS has the edge over FRHC on profitability, with a higher operating margin.
FRHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$420.8M | -193% |
| Q1 2026 | -$1.6B | -221% |
| Q4 2025 | $651.7M | +$744.4M |
| Q3 2025 | $456.4M | +$903.8M |
| Q2 2025 | $450M | -46% |
| Q1 2025 | $1.3B | +330% |
| Q4 2024 | -$92.7M | -$54.2M |
| Q3 2024 | -$447.5M | -$1.1M |
FRHC's free cash flow was −$884M over the past year, against $1.2B the year before. Free cash flow isn't a meaningful measure for financial services companies like FRHC.
MS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$46B | -$42.7B |
| Q2 2026 | -$2.7B | -123% |
| Q1 2026 | -$7.1B | +$16.9B |
| Q4 2025 | -$2.4B | -120% |
| Q3 2025 | -$3.3B | +$14B |
| Q2 2025 | $11.8B | +368% |
| Q1 2025 | -$24B | -650% |
| Q4 2024 | $11.8B | +$29.6B |
MS has the edge over FRHC on cash flow, with more consistent year-over-year improvement.
FRHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +152K shares |
| 1 year | +0.3% | +212K shares |
| 3 years | +4.8% | +2.8M shares |
FRHC has 61M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2022 | — |
MS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -3M shares |
| 1 year | -1.5% | -24M shares |
| 3 years | -4.7% | -77M shares |
| 5 years | -14% | -246M shares |
| Available history | -4.5% | -74M shares |
MS has the edge over FRHC on shareholder dilution, with a more favorable share count trend.
FRHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 3.2x | Elevated |
| Q3 2025 | 1.6x | Healthy |
| Q2 2025 | 0.8x | Very low |
| Q1 2025 | -2.8x | Net Cash |
| Q4 2024 | -0.3x | Net Cash |
| Q3 2024 | -0.8x | Net Cash |
FRHC has the edge over MS on leverage, with a lower net debt burden relative to earnings.
MS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 7.8x | High |
| Q2 2026 | 7.3x | High |
| Q1 2026 | 8.2x | High |
| Q4 2025 | 8.6x | High |
| Q3 2025 | 8.4x | High |
| Q2 2025 | 8.7x | High |
| Q1 2025 | 8.7x | High |
| Q4 2024 | 7.9x | High |
MS's net debt is about 7.8 years of its operating earnings (EBITDA), down from 8.4 years a year ago. Net leverage isn't a meaningful measure for financial services companies like MS.
FRHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 67.7 | Neutral |
FRHC's weekly RSI is 48 (neutral) and its Stochastic is 68 (neutral).
MS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 18.7 | Oversold |
MS's weekly RSI is 45 (neutral) and its Stochastic is 19 (oversold).
FRHC PE vs Financial Services Sector
| Metric | FRHC | Sector median | Relative |
|---|---|---|---|
| PE | 62x | 13x | 380% above |
| PE % | 75 | 63 | 12 pts above |
FRHC is trading at 62x earnings, a 380% premium to the Financial Services sector's median of 13x.
MS PE vs Financial Services Sector
| Metric | MS | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 13x | 15% above |
| PE % | 59 | 63 | 4 pts below |
MS has the edge over FRHC on valuation relative to its sector.
FRHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $173.9 | 9.1% below |
| 20 week MA | $165.5 | 4.5% below |
| 50 week MA | $147.5 | 7.1% above |
| 100 week MA | $149.1 | 6% above |
| 200 week MA | $116.0 | 36% above |
FRHC has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 36% above its 200-week average.
MS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $186.5 | 1.5% above |
| 20 week MA | $203.3 | 6.9% below |
| 50 week MA | $191.9 | 1.4% below |
| 100 week MA | $164.9 | 15% above |
| 200 week MA | $129.3 | 46% above |
MS's trend is mixed: it's above three of its five weekly moving averages, and 46% above its 200-week average.
FRHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.9 | $52.1 | +250% |
| 2021 | $52.1 | $69.2 | +33% |
| 2022 | $69.2 | $57.9 | -16% |
| 2023 | $57.9 | $80.6 | +39% |
| 2024 | $80.6 | $129.7 | +61% |
| 2025 | $129.7 | $131.3 | +1.2% |
| 2026 YTD | $131.3 | $158.0 | +20% |
FRHC has the edge over MS on returns for 2026, with the stronger performance.
MS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.1 | $68.1 | +33% |
| 2021 | $68.1 | $99.3 | +46% |
| 2022 | $99.3 | $86.1 | -13% |
| 2023 | $86.1 | $93.3 | +8.3% |
| 2024 | $93.3 | $126.8 | +36% |
| 2025 | $126.8 | $181.9 | +43% |
| 2026 YTD | $181.9 | $189.2 | +4% |
MS has finished higher in five of the last six years. It's up 4% so far in 2026.